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Abstract
Background: Previous studies have shown beneficial effects of mesenchymal stem cell (MSC) transplantation in
central nervous system (CNS) injuries, including traumatic brain injury (TBI). Potential repair mechanisms involve
transdifferentiation to replace damaged neural cells and production of growth factors by MSCs. However, few
studies have simultaneously focused on the effects of MSCs on immune cells and inflammation-associated
cytokines in CNS injury, especially in an experimental TBI model. In this study, we investigated the anti-inflammatory
and immunomodulatory properties of MSCs in TBI-induced neuroinflammation by systemic transplantation of MSCs
into a rat TBI model.
Methods/results: MSCs were transplanted intravenously into rats 2 h after TBI. Modified neurologic severity score
(mNSS) tests were performed to measure behavioral outcomes. The effect of MSC treatment on neuroinflammation
was analyzed by immunohistochemical analysis of astrocytes, microglia/macrophages, neutrophils and T
lymphocytes and by measuring cytokine levels [interleukin (IL)-1α, IL-1β, IL-4, IL-6, IL-10, IL-17, tumor necrosis
factor-α, interferon-γ, RANTES, macrophage chemotactic protein-1, macrophage inflammatory protein 2 and
transforming growth factor-β1] in brain homogenates. The immunosuppression-related factors TNF-α stimulated
gene/protein 6 (TSG-6) and nuclear factor-κB (NF-κB) were examined by reverse transcription-polymerase chain
reaction and Western blotting. Intravenous MSC transplantation after TBI was associated with a lower density of
microglia/macrophages and peripheral infiltrating leukocytes at the injury site, reduced levels of proinflammatory
cytokines and increased anti-inflammatory cytokines, possibly mediated by enhanced expression of TSG-6, which
may suppress activation of the NF-κB signaling pathway.
Conclusions: The results of this study suggest that MSCs have the ability to modulate inflammation-associated
immune cells and cytokines in TBI-induced cerebral inflammatory responses. This study thus offers a new insight
into the mechanisms responsible for the immunomodulatory effect of MSC transplantation, with implications for
functional neurological recovery after TBI.
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Background
Traumatic brain injury (TBI) is a major cause of mortality
and morbidity among the population worldwide [1]. The
inflammatory response is regarded as a key factor in the
secondary injury cascade following TBI. Activation of the
inflammatory cascade is mediated by the release of
pro- and anti-inflammatory cytokines [2,3]. TBI induces a
strong inflammatory response characterized by the recruit-
ment of peripheral leukocytes into the cerebral parenchyma
and the activation of resident immune cells [4,5]. The infil-
tration of neutrophils, monocytes and lymphocytes to the
injured site directly affects neuronal survival and death
[4-7]. Moreover, activated microglia migrate to injured sites
and release cytokines, chemotactic cytokines, reactive
oxygen species, nitric oxide, proteases and other factors
with cytotoxic effects, which may in turn exacerbate
neuronal death [6,8].
However, these immune cells and inflammatory mediators
can also have neuroprotective effects in TBI [3,9]. For
example, T lymphocytes may contribute to later repair
processes in brain injury [10,11]; proinflammatory
cytokines such as interleukin (IL)-1, IL-6 and tumor
necrosis factor (TNF)-α have both deleterious and
beneficial effects on neural cells [7,12,13]; and microglia
can remove cell debris, promote tissue remodeling and
exert numerous neuroprotective effects under certain
conditions [4,14,15]. Of these, TBI-induced inflammation
appears to be a key factor in secondary brain damage,
which suggests that anti-inflammatory or immunoregula-
tory strategies could provide effective treatments for the
management of TBI-induced pathology.
Previous studies have shown beneficial effects of
mesenchymal stem cell (MSC) transplantation in central
nervous system (CNS) injuries, including TBI, stroke and
spinal cord injury animal models. The main findings of
these studies suggested that MSCs improved neurological
functional recovery, decreased apoptosis, increased en-
dogenous cell proliferation, promoted angiogenesis and
reduced lesion size [16]. The potential mechanisms
whereby transplanted MSCs might exert beneficial effects
in CNS injury include their ability to migrate to injured
tissues, transdifferentiation to replace damaged neural
cells and the production of growth factors by MSCs
[16-18]. However, recent evidence indicates that the
therapeutic effect of MSC transplantation may not be
through direct cell replacement, but via modulating
the host microenvironment [19]. MSCs can secrete a
variety of bioactive molecules such as trophic factors
and anti-apoptotic molecules, which may provide the main
mechanism responsible for their therapeutic effect [20].
More recently, many studies have demonstrated that
MSCs possess immunomodulatory properties [21,22].
MSCs can directly inhibit the proliferation of T lym-
phocytes and microglial cells, and can modulate the
cytokine-secretion profile of dendritic cells and monocytes
and/or macrophages [20,23-25]. MSCs are also known to
inhibit basal and formyl-methionyl-leucyl-phenylalanine-
stimulated production of reactive oxygen species by neutro-
phils [26]. In experimental autoimmune encephalomyelitis
models, MSCs inhibited myelin-specific T cells and induced
peripheral tolerance [27,28]. The immunosuppressive effect
of transplanted MSCs has also been demonstrated in acute,
severe graft-versus-host disease [29] and in multiple system
atrophy [30]. In addition, MSCs can induce peripheral
tolerance and migrate to injured tissues, where they can
inhibit the release of proinflammatory cytokines and
promote the survival of damaged cells [21]. For example,
the therapeutic benefit of MSC transplantation has been
observed in acute lung injury [31,32], myocardial infarc-
tion [33], acute renal failure [34], cerebral ischemia [35]
and Alzheimer’s disease [36]. Furthermore, some stud-
ies have found an inflammation-modulatory function
for transplanted stem cells. One study demonstrated
anti-inflammatory effects of human cord blood cells
in a rat model of stroke [37]. Another study reported that
intravenous NSCs, administered during the hyperacute
stage in stroke, could modulate innate cerebral inflamma-
tory responses by interacting with peripheral inflammatory
systems [38].
These studies indicate the feasibility of using MSCs to
reduce cerebral inflammation and modulate the immune
response after TBI. However, few studies have focused
simultaneously on the effects of MSCs on inflammation-
associated cytokines and immune cells in CNS injury,
especially in an experimental TBI model. In this study,
we therefore investigated the anti-inflammatory and
immunomodulatory properties of MSCs in TBI-induced
neuroinflammation using systemic MSC transplantation
in a rat TBI model.
Materials and methods
Sprague–Dawley (SD) rats were purchased from the
Animal Experiment Center of Southern Medical University
(Guangzhou, China). Animals were housed under a 12-h
light/dark cycle, with food and water freely available.
Animal experimental procedures were approved by the
Southern Medical University Ethics Committee. All surgery
was performed under sodium pentobarbital anesthesia, and
all efforts were made to minimize animal suffering.
Isolation, expansion and characterization of MSCs
MSCs were generated from the bone marrow of SD rats.
Mononuclear cells were isolated by gradient centrifugation
at 900 g for 30 min on Percoll (Invitrogen, Carlsbad, CA,
USA) at a density of 1.073 g/ml. The cells were then
washed twice with phosphate-buffered saline (PBS) and
plated at 1 × 106 cells/25 cm2 in culture flasks in 5 ml
DMEM/F12 (1:1) with 10% fetal bovine serum. After 72 h
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of incubation, non-adherent cells were removed from the
cultures, and fresh culture medium was added to the flasks.
When the cells reached 90% confluence, adherent cells
were trypsinized, harvested and expanded [39]. Expanded
cells from passages three−eight were used for further
testing or transplantation.
MSCs were assessed by flow cytometry analysis of CD44,
CD90 and CD105, and the hematopoietic markers CD14,
CD34, CD45 and HLA-DR [40]. The primary antibodies
used were fluorescein isothiocyanate-conjugated anti-
CD44, -CD45 and -CD105, and phycoerythrin-conjugated
anti-CD14, -CD34, -CD90 and -HLA-DR. All antibodies
were purchased from AbD Serotec (1:10, Kidlington, UK).
Experimental groups
SD rats were divided into three groups: (1) sham group
(21 rats); (2) TBI + saline group (52 rats); (3) TBI + MSCs
group (52 rats).
Traumatic brain injury animal models
TBI animal models were produced as previously described
[41]. Adult male SD rats (220–250 g) were anesthetized
with 2% pentobarbital (30 mg/kg) intraperitoneally and
maintained at 37°C throughout the surgical procedure
using a water-heating pad. The rats were placed in a stereo-
tactic frame. A 6-mm-diameter craniotomy was performed
over the right cortex midway between the lambda and the
bregma. Injury was induced using a weight-drop hitting
device (ZH-ZYQ, Electronic Technology Development Co.,
Xuzhou, China) with a 4.5-mm-diameter cylinder bar
weighing 40 g from a height of 20 cm. Rats in the sham
group were subjected to the same craniotomy procedure
without cortical impact.
MSC transplantation
Two hours after TBI, the rats were neurologically evaluated
using a modified neurological severity score (mNSS) test.
Rats with similar neurological severity scores (13–15 points)
were randomly divided into two groups that received
4 × 106 MSCs in 100 μl PBS or PBS alone, respectively, via
the jugular vein.
Behavioral testing
Behavioral testing was conducted on days 1, 3, 7, 14, 21
and 28 after TBI using mNSS tests. The mNSS test
includes motor, sensory, reflex and balance tests, as de-
scribed previously [42]. The mNSS test is graded on a
scale of 0–18, where a total score of 18 points indicates
severe neurological deficit and a score of 0 indicates
normal performance; 13–18 points indicates severe
injury, 7–12 indicates mean-moderate injury, and 1–6
indicates mild injury.
Measurements of brain water content
Brain water content was measured at 72 h after TBI.
Following anesthesia and decapitation, the brains were
removed immediately and divided into two hemispheres
along the midline, and the cerebella were removed.
Ipsilateral hemispheres were placed on a pre-weighed
piece of aluminum foil to give the wet weight and
then dried in an electric oven at 100°C for 24 h [38].
The brain water percentage was calculated as follows:
(wet weight - dry weight)/(wet weight).
Immunohistochemistry and terminal deoxynucleotidyl
transferase dUTP nick end labeling staining
At 72 h after TBI, rats were anesthetized and transcardially
perfused with 100 ml cold PBS and 100 ml of 4% parafor-
maldehyde in 0.1 M PBS. The brains were then removed,
post-fixed and paraffin-embedded, and consecutive coronal
sections were cut at 5-μm intervals from bregma −2.0 mm
to bregma −7.0 mm to collect the entire lesioned cortex.
For immunohistochemistry, slides with brain sections were
deparaffinized and boiled in 10 mM citrate buffer (pH 6.0)
in a microwave to expose the antigens and then blocked
with 10% normal goat serum. Slides were incubated
with primary antibody against glial fibrillary acidic
protein (GFAP) (rabbit polyclonal to GFAP, 1:200),
microglia/macrophage-specific calcium-binding protein
(goat polyclonal to Iba1, 1:100, Abcam, New Territories,
HK), myeloperoxidase (MPO) (rabbit polyclonal to MPO,
1:100, Abcam) and CD3 (rabbit polyclonal to CD3, 1:100,
Abcam) at 4°C overnight. Following primary antibody
incubation, slides were incubated in biotin-conjugated
anti-rabbit IgG or anti-goat IgG (1:100, Boster, Wuhan,
China), then treated with an avidin-biotin-peroxidase
system (Boster) (negative controls for immunostaining was
secondary antibody only). Finally, slides were stained with
diaminobenzidine, and the nucleus was counterstained
with hematoxylin. Terminal deoxynucleotidyl transferase-
mediated dUTP nick 3′-end labeling was performed to
detect dying cells using an In Situ Cell Detection Kit
(Roche, South San Francisco, CA, USA) according to the
manufacturer’s instructions. The number of positive cells
near the injured areas was counted (8 to10 sections per
brain, 500 μm apart) in a blinded manner.
Cytokine analysis
To measure cytokine levels, rats were killed at 12, 24 and
72 h after TBI or sham operation. Brains were immediately
collected, and punch biopsies (5 mm diameter) of the
injured cortex were isolated and stored at −80°C. The tissue
was homogenized in chilled extraction buffer containing
Tris–HCl (50 mmol/l, pH 7.2), NaCl (150 mmol/l), 1%
Triton X-100 and 1 mg/ml protease inhibitor cocktail
(Biovision, Mountain View, CA, USA) at a ratio of 1:10
(tissue: buffer), shaken for 90 min on ice, centrifuged at
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12,000 g for 15 min at 4°C and frozen at −80°C [43]. Total
protein concentrations were measured using a BCA Protein
Assay Kit (Thermo, Rockford, IL, USA). The levels of 12
cytokines [IL-1α, IL-1β, IL-4, IL-6, IL-10, IL-17, tumor
necrosis factor (TNF)-α, interferon (IFN)-γ, RANTES,
macrophage chemotactic protein (MCP)-1, macrophage
inflammatory protein (MIP)-2 and transforming growth
factor (TGF)-β1] were determined in 1 mg of total protein
using the Rat Bio-Plex Pro Assays (Bio- Rad, Hercules, CA,
USA), according to the manufacturer’s instructions.
Quantitative real-time polymerase chain reaction
Total RNA was extracted from injured brain tissues at 12,
24 and 72 h after TBI using TRIzol Reagent (Invitrogen),
according to the manufacturer’s instructions. Levels of
TNF-α stimulated gene/protein 6 (TSG-6) and nuclear
factor (NF)-κB mRNA were quantitated using an ABI
7500HT Fast Real-Time PCR System (Applied Biosystems,
Grand Island, NY, USA). Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as an endogenous
control. Sequence-specific primers for the above genes







The 2-ΔΔCt method was used to calculate the relative
expression levels.
Western blot analysis
Total protein was isolated from rat injured brain tissues
using ice-cold RIPA buffer. Total protein concentrations
were measured with the BCA Protein Assay Kit (Thermo).
Protein samples (30 μg per lane) were separated using
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
and transferred to polyvinylidene difluoride membranes.
Proteins were detected by incubation with primary anti-
bodies (mouse polyclonal to TSG-6 and mouse anti-NF-κB
p65 1:250, BD Biosciences, San Jose, CA, USA) fol-
lowed by secondary antibodies (goat anti- mouse IgG,
horseradish-peroxidase conjugate, 1:1,000, Sigma Aldrich,
St. Louis, MO, USA). Immunoblots were visualized
using a Millipore ECL Western Blotting Detection System
(Millipore, Billerica, MA, USA). GAPDH (1:3,000, Santa
Cruz Biotechnology, Santa Cruz, CA, USA.) was employed
as the loading control.
Statistical analysis
Statistical analyses were performed using SPSS version
13.0 (SPSS, Chicago, IL, USA), and all data are presented
as mean ± S.D. Statistical differences among the groups
were assessed by one-way ANOVA and post hoc multiple
comparisons were performed using Student-Newman-Keuls
tests. The significance level was set at p < 0.05.
Results
Isolation and characterization of MSCs
MSCs were isolated from SD rats’ bone marrow and
maintained in culture for several passages. Before intra-
venous transplantation, third- and eighth-passage cells
were characterized, and flow cytometry analysis confirmed
that the cells at transplantation were positive for CD44
(99.01%), CD90 (99.28%) and CD105 (97.71%), and had
low expression of CD14 (0.79%), CD34 (0.78%), CD45
(0.67%) and HLA-DR (1.11%) (Figure 1).
Treatment with MSCs improved neurological recovery
after TBI
In order to assess the effects of systemic administration of
MSCs after TBI, mNSS was performed on days 1, 3, 7, 14,
21 and 28 after TBI. There was a significant improvement
in neurological function in the MSC-treated group
compared with the PBS group from days 3–28 post-TBI
(p < 0.05). There was no significant difference between
the scores in the two groups only at 24 h post-TBI
(Figure 2A).
MSC treatment reduced brain water content after TBI
To investigate whether treatment with MSCs could
reduce brain edema, we measured brain water contents
in the two experimental groups. Increased water content
directly causes brain edema, which is one of the most
important surrogate markers of brain damage, and it
peaks at 72 h after brain injury [44]. The PBS group had
a significantly higher brain water content than the
sham-injured control group. However, treatment with
MSCs significantly reduced the brain water contents
compared with the PBS group (p < 0.05). The brain
water contents in the sham, PBS and MSC groups were
78.62 ± 0.32, 82.48 ± 0.74% and 79.87 ± 0.70%, respectively
(Figure 2B).
MSC treatment reduced brain inflammatory cell
infiltration, microglia and apoptotic cell numbers
To test the effects of MSC treatment on the number of
peripheral infiltrating and resident immune cells in the
injured brain, we identified GFAP+ astrocytes, Iba-1+
microglia cells/macrophages, MPO+ neutrophils and
CD3+ lymphocytes by immunohistochemistry. The dens-
ities of astrocytes were not significantly different after
MSC treatment (Figure 3B,D). The number of microglia/
macrophages (sham: 142. 7 ± 45. 4 cells/mm2; PBS: 1,524.
7 ± 60.1 cells/mm2; MSCs: 1,124.3 ± 104.5 cells/mm2)
(Figure 3C,E) was significantly reduced after MSC
Zhang et al. Journal of Neuroinflammation 2013, 10:106 Page 4 of 12
http://www.jneuroinflammation.com/content/10/1/106
administration at 72 h post-TBI compared with the PBS
treatment group (p < 0.05). Meanwhile, MSCs decreased
the densities of infiltrated MPO+ neutrophils (PBS: 775.0 ±
55.34 cells/mm2; MSCs: 638.67 ± 72.15 cells/mm2)
(Figure 4A,C) and CD3+ lymphocytes (PBS: 421.67 ± 28.15
cells/mm2; MSCs: 367.67 ± 17.5 cells/mm2) (Figure 4B,D)
and apoptotic cells (sham: 18. 7 ± 8.1 cells/mm2; PBS:
295 ± 15 cells/mm2; MSCs: 179.3 ± 25.8 cells/mm2)
(Figure 5) in the injured cortex at 72 h post-TBI (p < 0.05).
MSCs influenced cytokine levels in injured cortex
To investigate the anti-inflammatory functions of MSCs,
we assessed an array of inflammatory cytokines in injured
cortex homogenates at 12, 24 and 72 h after TBI (Figure 6).
Levels of the proinflammatory cytokines IL-1β at 12 h
(p < 0.01), 24 h (p < 0.05) and 72 h (p < 0.05), IL-6
at 24 h (p < 0.05) and 72 h (p < 0.05), IL-17 at 24 h
(p < 0.05) and 72 h (p < 0.01), TNF-α at 24 h (p < 0.05)
and 72 h (p < 0.01), and IFN-γ at 72 h (p < 0.05) were all
significantly decreased in the MSC-treatment group
compared with the PBS group (Figure 6A-E). In contrast,
production of the anti-inflammatory cytokines IL-10 at
24 h (p < 0.01) and 72 h (p < 0.05) and TGF-β1 at
24 h (p < 0.01) and 72 h (p < 0.01) (Figure 6F,G)
after TBI were increased in the MSC-treatment group
compared with the PBS group. The chemokines MCP-1,
Figure 1 Surface marker expression in MSCs. MSCs were confirmed by flow cytometry analysis after three passages as positive for CD44
(99.01%), CD90 (99.28%) and CD105 (97.71%), with low positivity for CD14 (0.79%), CD34 (0.78%), CD45 (0.67%) and HLA-DR (1.11%).
Figure 2 Modified neurologic severity score (mNSS) and brain water content. (A) Neurological function was analyzed by mNSS on days 1,
3, 7, 14, 21 and 28 after TBI. Treatment with MSCs significantly lowered mNSS from days 3–28 compared with the PBS group. There was no
significant difference in scores between the MSC- and PBS-treated groups only at 24 h post-TBI (n = 6 per group). (B) Brain water content of
ipsilateral hemispheres was measured at 72 h after injury. The PBS group had a significantly higher brain water content than the sham-injured
control group. MSC treatment significantly reduced brain water content compared with the PBS group (n = 6 per group). Data are presented as
the mean ± SD. *p < 0.05, **p < 0.01.
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MIP-2 and RANTES were reduced at 12, 24 and 72 h after
TBI in the MSC group compared with the PBS group
(Figure 6H-J). There were no significant differences in
levels of the cytokines IL-1α and IL-4 (Figure 6K,L)
between the two groups.
MSC treatment upregulated TSG-6 expression
To elucidate the potential mechanisms responsible for
the effects of MSCs on anti-inflammatory and immuno-
modulatory properties, we analyzed the expression of
the inhibitory factors TSG-6 and transcription factor
NF-κB at the mRNA and protein levels. TSG-6 was
upregulated from 12–72 h in the injured cortex after
TBI in the MSC-treatment group (p < 0.01) (Figure 7A).
mRNA levels of NF-κB (Figure 7B) were decreased from
12–48 h after MSC transplantation (p < 0.01). Similar
results were obtained by Western blotting for TSG-6
and NF-κB p65 (Figure 7C).
Discussion
In this study, we investigated the anti-inflammatory and im-
munomodulatory properties of MSCs by systemic trans-
plantation into TBI model rats. The main observations
were that MSC treatment reduced the presence of micro-
glia/macrophages in the damaged brain parenchyma and
decreased the density of peripheral infiltrating leukocytes at
the injured site, as well as reducing proinflammatory cyto-
kines and increasing anti-inflammatory cytokines, possibly
through enhanced expression of TSG-6. TSG-6 may, in
turn, act by suppressing activation of the NF-κB signaling
Figure 3 Effect of MSC treatment on GFAP+ astrocytes and Iba-1+ microglia/macrophages. (A) Diagram of a coronal rat brain section
showing the relationship of the lesion cavity (red) to the regions photographed (blue squares). The density of astrocytes was not significantly different
after MSC treatment (B, D) (n = 6 per group). The number of microglia/macrophages (C, E) (sham: 142.7 ± 45.4 cells/mm2; PBS: 1,524.7 ± 60.1 cells/mm2;
MSCs: 1,124.3 ± 104.5 cells/mm2) was significantly decreased after MSC administration at 72 h post-TBI compared with the PBS-treatment group
(n = 6 per group). Data are presented as mean ± SD. Bar = 50 μm. *p < 0.05.
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pathway and decreasing the production of proinflammatory
cytokines to initiate a proinflammatory cytokine cascade.
Proinflammatory cytokines such as TNF-α, IL-1 and IL-6
are produced mainly by microglia, with some also produced
by astrocytes, neurons and endothelial cells, which in turn
activate glial cells, inducing further cytokine production
and astrogliosis [4,45,46]. Reduced activation of microglia
can thus reduce inflammation and improve histological and
functional outcomes after TBI [8]. Anti-inflammatory
cytokines such as IL-4, IL-10 and TGF-β1 have the ability
to counteract and downregulate inflammatory and cyto-
toxic reactions [4,47]. For instance, IL-10 is produced by
microglia and astrocytes and by lymphocytes in the periph-
ery, and can suppress microglia and astroglia activation, as
Figure 4 Influence of MSC administration on MPO+ neutrophils and CD3+ lymphocytes. MSCs reduced the numbers of infiltrating
MPO+ neutrophils (A, C) (PBS: 775.0 ± 55.34 cells/mm2; MSCs: 638.67 ± 72.15 cells/mm2), CD3+ lymphocytes (B, D) (PBS: 421.67 ± 28.15 cells/mm2;
MSCs: 367.67 ± 17.5 cells/mm2). Data are presented as the mean ± SD. Bar = 50 μm; n = 6 per group, *p < 0.05.
Figure 5 Effect of MSC transplantation on apoptosis. Apoptotic cells (sham: 18.7 ± 8.1 cells/mm2; PBS: 295 ± 15 cells/mm2;
MSCs: 179.3 ± 25.8 cells/mm2) in the injured cortex at 72 h after TBI were reduced in the MSC treatment group compared with the PBS group
(A, B) (n = 6 per group). Number of apoptotic cells is presented as the mean ± SD. Bar = 50 μm. **p < 0.01.
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well as decreasing production of proinflammatory cy-
tokines [48,49]. MSCs have been shown to decrease
proinflammatory cytokine gene expression in experimental
acute lung injury [31,32], myocardial infarction [33] and
acute renal failure [34] and to upregulate IL-10 expression
in rat models of myocardial infarction and cerebral
infarction [50,51]. Although astrocytes are not directly
immune-related cells, activated astrocytes are a major
source of inflammatory-related molecules such as
pro- and anti-inflammatory cytokines and chemokines.
In addition, astrocyte activation and proliferation after
TBI seem to impair axonal regrowth, but these cells
also release neurotrophic factors promoting tissue
repair and neurogenesis [52]. However, the immuno-
modulatory effects of MSCs on astrocytes are still
limited. One study has shown that MSCs can inhibit
the production of cytokines in LPS-activated astrocyte
cultures, reducing not only the proinflammatory cytokines,
but also the expression of the anti-inflammatory IL-10 [53].
In the CNS, chemokines secreted by glia and neurons are
considered to be essential mediators in the recruitment of
leukocytes into damaged parenchyma in post-traumatic
neuroinflammation [43]. MIP-2, also known as CXCL2,
contributes to neutrophil infiltration and subsequent
secondary neurodegeneration following TBI [54], and it has
been shown to increase rapidly following TBI in experi-
mental TBI models [55,56]. MCP-1, also known as CCL2,
is the most potent chemoattractant for monocytes, macro-
phages and microglia, which play significant roles in medi-
ating post-traumatic secondary brain damage [43]. CCL2
expression is elevated rapidly after diffuse axonal injury,
and its overexpression exacerbated ischemic brain injury in
Figure 6 Influence of MSC treatment on cytokine concentrations. Levels of the proinflammatory cytokines IL-1β (at 12, 24 and 72 h), IL-6
(at 24 and 72 h), IL-17 (at 24 and 72 h), TNF-α (at 24 and 72 h) and IFN-γ (at 72 h) were significantly decreased in the MSC-treatment group
compared with the PBS group (A–E). Levels of the anti-inflammatory cytokines IL-10 and TGF-β1 (at 24 and 72 h after TBI) (F, G) were increased
in the MSC-treatment group compared with the PBS group. The chemokines MCP-1, MIP-2 and RANTES were reduced at 12, 24 and 72 h after TBI
in the MSC group compared with the PBS group (H–J). There were no significant differences in levels of the cytokines IL-1α and IL-4 (K, L)
between the two groups. n = 6 in each time point of per group. Data are presented as the mean ± SD. *p < 0.05, **p < 0.01.
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mice [57,58]. Expression of the chemokine RANTES
(regulated upon activation, normal T cell expressed
and secreted) increased after brain injury in rats and
has the ability to activate T cells [59]. The role of T
lymphocytes in TBI is largely unknown, although in
ischemic stroke, these cells infiltrate into the brain
and release proinflammatory cytokines and cytotoxic
substances, which contribute to early inflammation
and brain injury [10]. One study has shown that
reduction of T-lymphocyte recruitment significantly
enhances tissue preservation and functional outcome
after spinal cord injury [60]. Therefore, reduction of
neutrophil and T lymphocyte infiltrations at an early
stage is a key feature in improving TBI outcome [61].
In contrast, T lymphocytes can also have beneficial
effects on the repair and regeneration of the brain at
later stages following injury [10]. Our results indicated
that MSCs reduce production of the chemokines MIP-2,
MCP-1 and RANTES, suggesting that they could act
through reducing chemokine production, thus decreasing
the recruitment of peripheral leukocytes.
The anti-inflammatory and immunosuppressive effects
of MSCs were related to several inhibitory factors
such as inducible nitric oxide synthase, indoleamine
2,3-dioxygenase, prostaglandin E2 and TSG-6, which
are produced by MSCs or released following cross-talk
with target cells, and which have been reported to be
involved in MSC-mediated immune regulation [22]. The
current study did not investigate inhibitory factors pro-
duced by MSCs, such as inducible nitric oxide synthase,
indoleamine 2,3-dioxygenase or prostaglandin E2, because
their short half-lives mean that their immunosuppressive
effects can only be observed in vitro or because they
have adverse effects when administered systemically
[62]. TSG-6 is an anti-inflammatory protein with multiple
anti-inflammatory effects that is induced by the inflamma-
tory cytokines TNF-α and IL-1 [63]. Transplanted MSCs
played a crucial role in the suppression of inflammation in
models of myocardial infarction and corneal injury, and
these anti-inflammatory effects may be attributable to the
secretion of TSG-6 by MSCs [33,64]. NF-κB is an import-
ant transcription factor that regulates many genes with key
roles in immune and inflammatory responses. It is activated
in the brain after TBI and contributes to neuronal death
[65,66]. Inhibition of NF-κB activation may thus reduce
adverse inflammatory response events and reduce the loss
of neuronal cells after TBI. TSG-6 can reduce the produc-
tion of proinflammatory cytokines through suppressed acti-
vation of the NF-κB signaling pathway, thus initiating the
cascade of proinflammatory cytokines [67]. Our results
suggest that the beneficial effects of MSCs may be partially
explained by the effect of TSG-6 on the NF-κB pathway.
The results of this study raise several issues regarding the
clinical use of MSCs. First, the schedule of MSC adminis-
tration is important. MSCs are not spontaneously immuno-
suppressive and only exhibit this property under special
conditions [22]; stimulation with certain inflammatory
cytokines such as IFN-γ is essential for MSC-mediated
immunosuppression [68]. If the levels of inflammatory
cytokines are too low, the immunosuppressive effect of
Figure 7 MSC treatment upregulates TSG-6 and downregulates NF-κB expression. Upregulation of TSG-6 (A) was observed from 12 to 72 h
in the injured cortex after TBI in the MSC-treatment group. mRNA levels of NF-κB (B) decreased from 12 to 48 h after MSC transplantation. Similar
results were observed at the protein level (C) for TSG-6 and NF-κB p65. n = 6 in each time point of per group. Data are presented as the mean ± SD.
*p < 0.05, **p < 0.01 versus PBS group.
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MSCs will not be triggered. Inflammatory cytokines are rap-
idly upregulated following brain injury, and some peak at as
little as 2 h after TBI [7]. In addition, neutrophil and T
lymphocyte infiltrations peak at 24 h after TBI [61], and
microglia activation is induced immediately after injury
[69,70]. Later MSC treatment may therefore not be effective
in terms of anti-inflammatory or immunosuppressive activ-
ity, while MSC administration at the onset of the inflamma-
tory response after TBI is more likely to be effective. In this
study, we therefore transplanted MSCs at 2 h after TBI. Sec-
ond, the route taken by the cells is also important. Previous
studies showed that in the case of intravenously injected
MSCs, few cells reached the brain parenchyma after the
pulmonary first-pass effect [16]. The ideal treatment com-
bined intravenous injection with direct injection to provide
both systemic and local therapeutic effects [21]. Finally,
multiple administrations of MSCs may be needed to sustain
and prolong their inhibitory effects, as demonstrated in a
mouse graft-versus-host disease model [71].
MSCs are known to modulate both systemic and local
inflammation systems in neuroinflammation [72]. We did
not investigate the effect of MSCs on systemic inflamma-
tion, but the possibility that the neuroprotective effects of
MSCs are caused by modulation of the systemic inflamma-
tory system cannot be ruled out. Recent evidence suggests
a link between brain injury and the autonomic release of
proinflammatory cytokines by resident macrophages in the
spleen [73]. Inhibiting this release by splenectomy was
shown to improve outcomes in animal models of TBI
[44], implying that transplanted MSCs acting directly on
resident macrophages in the spleen could contribute to the
neuroprotective effect. Overall, these results suggest that
novel MSC-mediated immunosuppression mechanisms
may be developed for the therapy of TBI.
Conclusions
These results suggest that MSCs have the ability to
modulate inflammation-associated cytokine release and
immune cells in TBI-induced cerebral inflammatory
responses. This study serves as the basis for future studies
and offers new insights into the mechanisms responsible
for the beneficial immunomodulatory effect of MSC
transplantation in terms of functional neurological
recovery after TBI. However, further studies are needed to
resolve outstanding issues regarding the clinical use of
MSCs in TBI.
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